tbuckley/cabot-search huggingface dataset:
Frequency and burden of patient-reported chemotherapy toxicities in community-based oncology practices.
Authors: Christopher Ryan Friese, Philip J. Stella, Beth Lavasseur, Paul T. Adams, Lauren Swafford, JoAnn Lewis, Kari Michigan Mendelsohn-Victor
Journal: Journal of Clinical Oncology (2014)

178 Background: Patient-reported outcomes measurement is recommended to improve care delivery. Toxicities are important to study given their impacts on treatment completion. We captured patient-reported toxicities in community-based oncology practices and identified toxicities associated with excess health care service use. Methods: We surveyed newly-diagnosed patients who completed their first chemotherapy cycle at 5 community practices. Exclusion criteria were prior cancer history, non-English speakers, psychiatric diagnosis, and clinical trial participation. At the second cycle return visit, patients completed a questionnaire that measured the severity of nausea, vomiting, diarrhea, constipation, mouth sores, intravenous catheter problem, pain, fever/chills, extremity edema, and dyspnea. These were rated on a 5-point scale (1= did not experience to 5 = very severe). Patients also reported unscheduled oncologist visits, emergency department visits, or inpatient hospitalization. Results: Of 117 eligible patients, 106 (91%) participated. Most patients (98%) were white, 25.5% were male, and the mean(SD) age was 60 (11) years. The most frequent diagnoses were breast (43%), lung (21%), colorectal cancer (13%), and non-Hodgkin lymphoma (13%). Between cycle 1 and 2, frequent severe or very severe toxicities were nausea (30%), pain (18%), diarrhea (9%), and mouth sores (9%). 15% of patients had an unscheduled oncologist visit, 18% had an emergency department visit, and 9% of patients were admitted. Nausea (11.3%) and diarrhea (6.6%) were frequent reasons for unscheduled oncology visits; nausea and pain (both 5%) for emergency department visits, and; pain and dyspnea (both 2%) for hospitalization. Conclusions: Patient-reported toxicity monitoring is feasible and informative in community-based oncology practices. Despite widespread antiemetic use, nausea is a pervasive problem for newly-treated patients and drives excess service use. Pain assessment and management strategies are needed to reduce emergency department visits and hospitalizations.
Zalypsis Possess Potent Antileukemic Effect through the Induction of a DNA Damage Response, Independently of the p53 Status.
Authors: Enrique Colado, Teresa Paíno, Enrique M Ocio, Patricia Maiso, Xi Chen, Stela Álvarez-Fernández, Jesús Martín-Sánchez, Lorena González, Laura San-Segundo, Mercedes Garayoa, Diego Fernández-Lázaro, Maria-Belén Vidriales, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Atanasio Pandiella, Jesús F. San-Miguel
Journal: Blood (2009)
Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial
Authors: E. Maiello, E. Martinelli, C. Cardone, T. Troiani, N. Normanno, S. Pisconti, R. Bordonaro, F. Giuliani, M. Biglietto, C. Barone, A.M. Rachiglio, V. Montesarchio, G. Tonini, S. Cinieri, D. Rizzi, A. Febbraro, T. Latiano, G. Modoni, G. Colucci, F. Ciardiello
Journal: Annals of Oncology (2016)
Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial
Authors: Graydon S. Meneilly, Christine Roy-Duval, Hasan Alawi, George Dailey, Diego Bellido, Carlos Trescoli, Helard Manrique Hurtado, Hailing Guo, Valerie Pilorget, Riccardo Perfetti, Hamish Simpson
Journal: Diabetes Care (2017)

OBJECTIVE To evaluate the efficacy and safety of lixisenatide versus placebo on glycemic control in older patients with type 2 diabetes uncontrolled on their current antidiabetic treatment. RESEARCH DESIGN AND METHODS In this phase III, double-blind, randomized, placebo-controlled, two-arm, parallel-group, multicenter trial, patients aged ≥70 years were randomized to receive once-daily lixisenatide 20 μg or placebo before breakfast concomitantly with their existing antidiabetic therapy (including insulin) for 24 weeks. Patients at risk for malnutrition or with moderate to severe cognitive impairment were excluded. The primary end point was absolute change in HbA1c from baseline to week 24. Secondary end points included change from baseline to week 24 in 2-h postprandial plasma glucose (PPG) and body weight. RESULTS A total of 350 patients were randomized. HbA1c decreased substantially with lixisenatide (−0.57% [6.2 mmol/mol]) compared with placebo (+0.06% [0.7 mmol/mol]) from baseline to week 24 (P &amp;lt; 0.0001). Mean reduction in 2-h PPG was significantly greater with lixisenatide (−5.12 mmol/L) than with placebo (−0.07 mmol/L; P &amp;lt; 0.0001). A greater decrease in body weight was observed with lixisenatide (−1.47 kg) versus placebo (−0.16 kg; P &amp;lt; 0.0001). The safety profile of lixisenatide in this older population, including rates of nausea and vomiting, was consistent with that observed in other lixisenatide studies. Hypoglycemia was reported in 17.6% of patients with lixisenatide versus 10.3% with placebo. CONCLUSIONS In nonfrail older patients uncontrolled on their current antidiabetic treatment, lixisenatide was superior to placebo in HbA1c reduction and in targeting postprandial hyperglycemia, with no unexpected safety findings.
Update of AMC 0201 study: A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (NCT00296335).
Authors: Baek-Yeol Ryoo, Yoon-Koo Kang, Young Joo Min, Dae Young Zang, Gyu Yeol Kim, Dae Hyun Yang, Se Jin Jang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim
Journal: Journal of Clinical Oncology (2012)

76 Background: Despite a continuing debate on the role of adjuvant chemotherapy, several studies have suggested that mitomycin-C (M) plus fluoropyrimidine (f) could improve the outcome of curatively resected advanced gastric cancer (AGC) patients (pts). To improve further the adjuvant Mf chemotherapy, we have prolonged the administration of oral fluoropyrimidine (F) and added cisplatin (P) to Mf (MFP) and performed a phase III randomized trial to determine whether this strategy could improve the 3-year relapse free survival (3yRFS) in curatively resected AGC pts (HR=0.63, α=0.05, β=0.1). Three year follow-up results were reported in 2008 ASCO meeting. Here we report long-term follow-up results for confirmation. Methods: Three to 6 wks after R0 resection, the pts who had postoperative stage II-IV were randomized to receive either Mf or MFP adjuvant chemotherapy. For Mf group, 20 mg/m 2 of M was iv injected and 4 wks later, 460-600 mg/m 2 /day of doxifluridine was administered orally for 3 months. For MFP group, the administration of doxifluridine was extended for a total of 12 months and 6 shots of monthly 60 mg/m 2 of cisplatin were added to Mf. Results: Between Feb 2002 and Aug 2006, a total of 871 pts were randomized (435 in Mf, 436 in MFP). Sixteen pts were excluded because of ineligibility (11 in Mf, 5 in MFP). Postoperative stages were II in 51.0%, IIIA in 31.1%, IIIB in 9.4%, and IV in 8.5% of pts. With a median follow up of 6.6 yrs in April 2011, a total of 353 events (relapse or death) have been observed. There was no difference in RFS between the two groups (HR, 1.10; 95% C.I. 0.89 – 1.35; p=0.3918; 5yRFS 61.1% in Mf and 57.9% in MFP). Difference in overall survival (OS) was also insignificant (HR, 1.11; 95% C.I. 0.89 – 1.39; p=0.3349; 5yOS 66.5% in Mf and 65.0% in MFP). Conclusions: Long-term follow-up results of AMC 0201 trial confirmed prolongation of doxifluridine administration and addition of cisplatin to adjuvant chemotherapy with mitomycin-C plus 3 months of doxifluridine did not improve the treatment outcome in curatively resected AGC pts.
Adiponectin Regulates Bone Mass via Opposite Central and Peripheral Mechanisms through FoxO1
Authors: Daisuke Kajimura, Ha Won Lee, Kyle J. Riley, Emilio Arteaga-Solis, Mathieu Ferron, Bin Zhou, Christopher J. Clarke, Yusuf A. Hannun, Ronald A. DePinho, X. Edward Guo, J. John Mann, Gerard Karsenty
Journal: Cell Metabolism (2014)
Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling.
Authors: Lars Bullinger, Claudia Scholl, Eric Bair, Konstanze Dohner, Stefan Frohling, Richard F. Schlenk, Robert Tibshirani, Hartmut Dohner, Jonathan R. Pollack
Journal: Blood (2004)
High Serum Level of APRIL Is Related to Increased Risk of Acute Gvhd
Authors: Soo-Jeong Kim, Yundeok Kim, Shin Young Hyun, Ji Eun Jang, Doh Yu Hwang, Yu Ri Kim, Hye Won Lee, June-Won Cheong, Jin Seok Kim, Yoo-Hong Min
Journal: Blood (2012)
Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC)
Authors: G. T. Budd, M. Cristofanilli, M. J. Ellis, A. Stopeck, J. Matera, M. C. Miller, G. V. Doyle, W. J. Allard, L. W. Terstappen, D. F. Hayes
Journal: Journal of Clinical Oncology (2005)

503 Background: We have previously reported that the presence of 5 or more circulating tumor cells (CTCs) in 7.5 mL of blood from women with measurable disease in metastatic breast cancer (MBC) is associated with a poor outcome (NEJM, 351:8, 781–791, 2004). Here we report the results of the CTC assay in 46 MBC patients with non measurable disease. Methods: CTCs were enumerated in 7.5mL whole blood at baseline and at 3 or 4 week follow-up intervals for a period of six months in 46 patients with non measurable MBC about to start a new systemic therapy. CTCs were immunomagnetically separated and fluorescently labeled using the CellSearch Kit. Only nucleated (DAPI+) cells with the phenotype EpCAM+, Cytokeratin 8, 18 and/or 19+, and CD45- were counted using the CellSpotter Analyzer. Results: Median Progression Free Survival (PFS) and Overall Survival (OS) were determined for patients with <5 or ≥5 CTC /7.5mL at baseline and at first follow-up. The percentage of patients that were alive at 12 months (AL12) after the blood draw, the frequency of patients with 5 or more CTCs and the significance between the two groups of patients (logrank) is indicated in the table below. Conclusions: Data relating the presence of CTCs in non-measurable MBC with PFS and OS were similar to the data previously reported for measurable MBC. The presence of CTC in MBC patients can be used as a surrogate marker for PFS and OS in MBC patients with non-measurable as well as measurable disease. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Immunicon Immunicon
Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).
Authors: Marcelo C. Pasquini, Waleska Perez, Mei-Jie Zhang, Richard F. Schlenk, Arnold Ganser
Journal: Blood (2005)
An Experimental Study on the Effects of Sensitized-Donor Lymphocytes Infusion after Non-Myeloablative Allo-Stem Cell Transplantation.
Authors: Bao-An Chen, Yan Zhang, Yan-Zhi Bi, Jia-Hua Ding, Gang Zhao, Dong-Xiang Zeng, Chong Gao, Yun-Yu Sun, Fei Fei, Ning-Na Chen
Journal: Blood (2005)
Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial
Authors: Y. Fujiwara, H. Ishigami, R. Fukushima, A. Nashimoto, H. Yabusaki, H. Imamoto, M. Imano, Y. Kodera, Y. Uenosono, K. Amagai, S. Kadowaki, H. Miwa, H. Yamaguchi, T. Yamaguchi, J. Kitayama
Journal: Annals of Oncology (2016)
Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma
Authors: Aneel Paulus, Sharoon Akhtar, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Pooja Advani, Thomas E. Witzig, George J Weiner, Sikander Ailawadhi, Joachim Gullbo, Stig Linder, Geraldo Otero-Colon, Kasyapa S. Chitta, Asher Alban Chanan-Khan
Journal: Blood (2015)
Factor VIIa Bound to Endothelial Cell Protein C Receptor Activates Protease Activated Receptor 1-Mediated Cell Signaling and Barrier-Protective Response In Endothelial Cells
Authors: Prosenjit Sen, Ramakrishnan Gopalakrishnan, Hema Kothari, Curtis Clark, Usha Pendurthi, L. Vijaya Mohan Rao
Journal: Blood (2010)
The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group
Authors: C. Peters-Engl, P. Konstantiniuk, C. Tausch, A. Haid, B. Hoffmann, M. Jagoutz-Herzlinger, F. Kugler, S. Redtenbacher, S. Roka, P. Schrenk
Journal: Journal of Clinical Oncology (2004)

562 Background: Preoperative breast biopsy might cause disaggregation of tumour cells and tumour cell spread. The purpose of this study was to investigate the impact of preoperative biopsy on the rate of metastases to the sentinel lymph node (SLN) of patients with primary breast cancer. Methods: We report the results of 2502 patients with primary breast cancer who were operated and a sentinel node biopsy was performed. The association of preoperative biopsy with the risk of SLN metastases was examined by regression analyses and tested for possible confounding well known factors for axillary node metastases. Results: 1892 Patients were available for final analyses. 1048 (55.4%) patients had a preoperative diagnosis done by fine needle aspiration or core biopsy. 642 (33.9%) patients had a positive SLN when conventional H&E and IHC staining was performed. Patients with preoperative breast biopsy showed a 1.37 fold (95% CI, 1.13–1.66) increased relative risk for SLN metastases on univariate analysis but this result was not persistent when analysis was adjusted for other relevant factors for axillary node metastases RR 1.06 (95% CI, 0.83–1.34). In addition, subgroup analyses of the risk for occult micro metastases to the SLN (detected by IHC only) on H&E negative cases, did as well not reveal an accessory risk for preoperative biopsy RR 1.04 (95% CI, 0.67–1.60). Conclusions: The conclusion of the present data is that preoperative breast biopsy does not cause artificial tumour cell spread to the SLN with possible impact on the natural history of breast cancer. An update will be presented. No significant financial relationships to disclose.
Biomarker analyses of PLK isoforms in breast cancer
Authors: Yan Y. Degenhardt, Katja Remlinger, Joel Greshock, Tal Zaks, Barbara Weber, Tona Gilmer
Journal: Cancer Research (2006)

1947  Polo-like kinases (PLK) are a family of serine threonine kinases that are critical regulators of cell cycle progression, mitosis, cytokinesis and DNA damage response. Although extensive studies have shown the elevated expression of PLK1 in many types of cancer, and PLK1 has been proposed to be potential target for cancer therapy, very few and often contradicting data exist for the role of PLK2 (SNK) and PLK3 (FNK) in cancer. Here we performed taqman analysis on 88 tumor DNA isolated from primary sporadic breast tumors to study copy number changes for PLK1 and PLK2, and found that PLK1 has no gene amplification but PLK2 gene is amplified in 42% of breast tumors. We further performed RT-taqman analysis using RNA isolated from 44 primary sporadic breast tumors to study the expression level of PLK1, PLK2 and PLK3. PLK1 was found to be overexpressed in 68% of breast tumors, PLK2 is overexpressed in 34% of breast tumors, and PLK3 expression is reduced in 91% of breast tumors comparing to normal breast tissue. We also performed statistical analysis to see correlation of the expression of the three PLK isoforms with different clinical measurements from the breast tumor patients. PLK1 expression is statistically significantly correlated with ‘poor’ diagnosis ( negative ER; high histological grade; high percentage of S-phase; high mitotic score; detectable p53) while PLK2 expression is significantly correlated with ‘good’ prognosis (no angiolymphatic invasion; positive ER and PR; low histological grade; negative HER2; undetectable p53). PLK1 is expressed more in breast tumors with higher mitotic index, as reflected by percentage of S-phase as well as the mitotic score, whereas, PLK2 expression seems to be inversely related to mitosis, as reflected by inverse correlation with both percentage of S-phase cells as well as Ki-67 score.
Predictable Recurrence by Regular Monitoring Minimal Residual Disease with Flowcytometry In the Patients with Both AML and ALL: A Single-Center Study of 158 Cases.
Authors: Chunrong Tong, Junfang Yang, Yuehui Lin, Xinhong Fei, Jie Zhao, Xian Zhang, Jiangying Gu, Tong Wu, Dao-Pei Lu, Hui Wang
Journal: Blood (2010)
Offer radiotherapy to all patients with painful bone metastases, say researchers
Authors: Jacqui Wise
Journal: BMJ (2017)

A single dose of radiotherapy should be offered to all patients with painful bone metastases, even those with poor expected survival, researchers have said. Their study, published in JAMA Oncology ,1 found that pain and the quality of life may improve as soon as 10 days after radiotherapy.

Radiotherapy is often used to treat bone metastases, and studies have …
Regulation of Plasmacytoid Dendritic Cells by Commonly Used Anti-Viral Vaccines,
Authors: Bernd Jahrsdörfer, Benedikt Nussbaum, Birgit Mandel, Daniel Busch, Verena Panitz, Angelika Vollmer, Thamara Beyer, Klaus-Michael Debatin, Dorit Fabricius
Journal: Blood (2011)
Second-line chemotherapy in advanced pancreatic cancer patients before nab-paclitaxel introduction. Retrospective study in Reggio Emilia Clinical Cancer Centre
Authors: L. Baldi, M. Panebianco, P. Giorgi Rossi, E. Di Felice, T. Cassetti, R. Sassatelli, E. Rondini, C. Boni, C. Pinto
Journal: Annals of Oncology (2016)
Accuracy of Children in Reporting Asthma Control As Determined By c-ACT (Childhood-Asthma Control Test)
Authors: Alysa G. Ellis, Niharika Rath, Lisa D. Henry, Lisa A. Meadows, Beth L. Roehm, Deborah G. Loman, Robert C. Strunk
Journal: Journal of Allergy and Clinical Immunology (2017)
TMOD-11. USING THE SLEEPING BEAUTY TRANSPOSASE SYSTEM TO GENERATE MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 AND H3K27M MUTATIONS
Authors: Flor M Mendez, Felipe J Nunez, Carl Koschmann, Alexandra Calinescu, Meghna Saxena, Neha Kamran, Sheeba Pawar, Marta Dzaman, Pedro R Lowenstein, Maria G. Castro
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine glioma (DIPG) is a very aggressive pediatric brainstem tumor for which there is no treatment. The most common mutation occurs on the amino terminal tail of histone H3 variants H3.1 and H3.3 changing a lysine to methionine at position 27 and this results in global hypomethylation of H3K27. Additionally, 24% of tumors harbor activating mutations in Activin-A receptor Type 1 (ACVR1) a bone morphogenetic (BMP) receptor of the transforming growth factor beta (TGF-β) family. We used the Sleeping Beauty Transposase (SB) system to deliver plasmids encoding oncogenic NRAS and a short hair pin for p53 (shP53) in combination with ACVR1 G328V or H3.1 K27M, or both, into the lateral ventricles of neonatal mice, to generate endogenous tumors with DIPG mutations. Tumor development in mice was monitored by measuring luciferase activity in vivo; animals that reached moribund stage were perfused and processed for histology. Our preliminary results indicate that tumors with ACVR1 G328V have an increased median survival (MS>133 dpi) as compared to our control groups: NRAS/shP53 group (MS=90 dpi) and NRAS/shp53/H3.1 K27M group (MS=92 dpi). Tumors harboring NRAS/shp53/ and ACVR1 G328V genetic alterations also do not express the oligodendrocyte transcription factor 2 (Olig2) by immunohistochemistry and western blot. In conclusion, we used the SB system to develop a mouse model of DIPG. We observed an increase in median survival and some phenotypic differences in tumors harboring the ACVR1 G328V mutation. The loss of Olig2 NRAS/shp53/ACVR1 G328V tumors is interesting because Olig2 has been associated with delayed tumor progression. In the future we aim to elucidate the mechanisms by which ACVR1 and H3.1 K27M mutations contribute to tumor initiation and progression in order to develop targeted therapies for DIPG. Work supported by NIH/NINDs, Leah’s Happy Hearts and Chad Tough Foundations.
Molecular Response to Tyrosine Kinase Inhibitors (TKIs) for Chronic Myeloid Leukemia (CML). an Update on Experience at Tawam Hospital, Abudhabi, UAE in the Light of ELN Guidelines
Authors: Arif Alam, Sabir Hussain, Amar Lal, Donna Lee, Jorgen Kristensen
Journal: Blood (2014)
Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients.
Authors: Elisabetta Antonioli, Alessandra Carobbio, Lisa Pieri, Alessandro Pancrazzi, Paola Guglielmelli, Federica Delaini, Vanessa Ponziani, Maria Chiara Susini, Rajmonda Fjerza, Alberto Bosi, Alessandro Rambaldi, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood (2009)
Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters: Interim Results of a Phase 2, Multicenter, Randomized, Double-Blind Study (NuCath).
Authors: Steven R. Deitcher, Stephan Moll, Howard D. Homesley, Luigi Bertoli, Peter Kenyon, Peter Swischuk, Luis Pena
Journal: Blood (2004)
Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515
Authors: Alison T. Stopeck, Joseph M Unger, Lisa M. Rimsza, Brent Farnsworth, Michael LeBlanc, Maria Iannone, Richard I Fisher, Thomas P. Miller
Journal: Blood (2010)
Intracerebellar Granulocytic Sarcoma Presenting as a First Manifestation of Relapse in Chronic Myelogenous Leukemia (CML) During Imatinib Mesylate Therapy: A Case Report and Literature Review.
Authors: Agustin Pimentel, Daniel A Forman, Sharon L Swierczynski, Anthony A Donato, Brian Le
Journal: Blood (2009)